Spinal Elements Announces FDA 510(k) Clearance of Lucent® 3D Additive Manufactured Interbody Devices

Spinal Elements, a spine technology company, today announced the first 510(k) clearance in the Lucent® 3D line of 3D-printed interbody devices.

Spinal Elements, in developing lucent 3D, has taken advantage of the unique capabilities of 3D printing by printing a functionally unique multi-component device in a single printing step.  The resulting Lucent 3D implant is comprised of a strut-and-lattice structure with a bone graft chamber access lid designed to allow the surgeon to deliver a large amount of tightly packed graft inside the interbody structure, maximizing the amount of graft material available for fusion. Furthermore, when the access lid to the graft chamber is closed, the lid is designed to help distribute the loads of the spine in order to reduce the incidence of subsidence by having more surface area available for load distribution.

 With the FDA clearance and upcoming release of the novel Lucent 3D system, Spinal Elements continues its long tradition of excellence and leadership in introducing novel design and materials science to interbody devices.  Spinal Elements was among the first companies to obtain interbody clearance for PEEK devices in 2005 and followed that in 2012 by being the first to apply Ti-Bond®, Spinal Elements’ brand of plasma-sprayed titanium, on the surface of its PEEK interbody devices.

“The FDA clearance of Lucent 3D allows Spinal Elements to differentiate itself in a crowded 3D-printed interbody market.  Lucent 3D’s novel design is meant to address the challenges surgeons have shared with us of other 3D-printed interbody devices – subsidence and the amount of bone graft material available for fusion,” stated President and CEO Jason Blain.  “We are thrilled to obtain this first clearance and look forward to building on this platform to complement our various procedural solutions.”

Spinal Elements is a technology-driven company headquartered in Carlsbad, California. A leading designer, developer, manufacturer and marketer of innovative medical devices used in spinal surgical procedures, Spinal Elements combines leading medical device technologies, biologics and instrumentation to create positive surgical outcomes that exceed surgeon and patient expectations. Spinal Elements has built a reputation delivering innovative and differentiated technologies that enable fundamental shifts in solutions for spine surgery. The company markets a complete portfolio of advanced spinal implant technologies.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”